HealthRX.com · Printable question sheet
EGRIFTA in your fifties or early sixties: label check sheet for the prescriber
A one-page record of the product you actually have, the label's own checks (cancer history, pituitary history, glucose, IGF-1, swelling) and the questions an age-specific study has not answered, to take to the prescriber.
The product in your hands
Copy these from the carton and vial label.
Product name on the cartonEGRIFTA WR or EGRIFTA SV
Strength printed on the vial
Your age today
Date started, or planned start
Label checks to go through together
- Any cancer now, or a past cancer and whether its treatment is finished
- Any past growth or tumor that was not cancer
- Pituitary surgery or tumor, head radiation or a head injury
- Blood sugar or HbA1c checked before starting
- New swelling, joint pain or hand numbness and tingling since starting
- Latest IGF-1 result and its date
- Steroid replacement or other daily medicines reviewed
- Any chance of pregnancy
Results to bring
| Date | IGF-1 | Glucose or HbA1c | Other test | What the prescriber said |
|---|---|---|---|---|
What the labels and the pharmacokinetic study report about age
- The pivotal trials enrolled adults aged 18 to 65, with a mean age of 48 at baseline.[1]
- There is no information on use above 65, and pharmacokinetics in elderly patients have not been established.[1]
- EGRIFTA WR and EGRIFTA SV are not substitutable, so follow the instructions written for the exact product you have.[1]
- The label says to monitor IGF-1 during treatment and to consider stopping if levels stay raised.[1]
- A population pharmacokinetic analysis of 38 people found age unrelated to tesamorelin pharmacokinetics within the range of ages studied.[2]
Stop the injection and get emergency help right away
- A rash over your body, hives, itching, trouble breathing, a fast heartbeat, swelling of the face or throat, feeling faint or fainting, or flushing of the skin.[1]
For the prescriber
- Does anything in my history make the cancer warning more important for me?
- Is my dose the one written for the exact product I was given?
- How often will you check my IGF-1 and blood sugar?
- Which of my other conditions or medicines will you watch more closely at my age?
- If I reach 65 while on treatment, does anything change?
Sources for the facts on this sheet
- Theratechnologies Inc., via DailyMed. EGRIFTA WR (tesamorelin) for injection, for subcutaneous use: prescribing information, patient information and instructions for use. Effective 2026-07-29. https://dailymed.nlm.nih.gov/dailymed/drugInfo.cfm?setid=839334d3-8c1d-4c26-9036-2ab524a6ea75
- González-Sales M, Barrière O, Tremblay PO, et al. Population pharmacokinetic analysis of tesamorelin in HIV-infected patients and healthy subjects. Clin Pharmacokinet 2015. PMID 25358450. https://pubmed.ncbi.nlm.nih.gov/25358450/
This sheet records information for a conversation with your prescriber or pharmacist. It does not replace their instructions or the medication's prescribing information.